Refine by
Hematopoietic Stem Cells Equipment & Supplies
83 equipment items found
by:Astraveus based inParis, FRANCE
Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes. We develop high quality genetically edited HSCs to cure an undisclosed hereditary blood disease. This development will be translatable: genetically edited HSCs can be used to treat multiple genetic diseases, including ...
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing human long-term hematopoietic stem cells (LT-HSCs) from human (non-embryo) induced pluripotent stem cells (iPSCs). HSCs are rare subsets of hematopoietic cells that are responsible for the life-long production of all blood cell lineages, and for ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Hemoglobinopathies: Sickle cell disease, ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action that is differentiated from any current ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
We are pursuing a number of diseases using an in vivo editing approach, focusing on hematopoietic stem cells and other tissue types, and we are excited about the progress we’ve ...
by:ABEC, INC. based inBethlehem, PENNSYLVANIA (USA)
Our conditionally-immortalized allogeneic cell lines are derived from hematopoietic stem cells and allows us to eliminate the need for recurring donors. From a single cell line, we can produce unlimited quantities of consistent fully-functional cells with targeted ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and ...
Manufactured by:Access Biologicals LLC based inVista, CALIFORNIA (USA)
Suitable for culturing neuronal cells & hematopoietic stem cells; Collected from controlled donor herds in the US; .2 micron filtered; mycoplasma, 9CFR113.53 & virus ...
Manufactured by:Sartorius CellGenix GmbH based inFreiburg, GERMANY
CellGenix Recombinant Human Flt-3L reliably supports the proliferation of hematopoietic stem cells (HSCs). CellGenix® rh Flt-3L is produced in our dedicated animal-free GMP facility ensuring maximum safety for optimal use in ATMP ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells may represent another exciting strategy to efficiently and safely edit multiple genes in blood ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, Hemogenyx Pharmaceuticals developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. CDX antibodies ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by Hemogenyx Pharmaceuticals’ Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. A patent for ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. NK cells are a unique class of immune ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
These mutations cause the misfolding and dysfunction of IDUA, which leads to the toxic buildup of large sugars in the bone, cartilage, cornea, heart and central nervous system (CNS). There is currently no cure for these patients; however, enzyme replacement therapy and hematopoietic stem cell transplant are used to manage the non-CNS symptoms. ...